

Nucleofill Strong Plus is a professional injectable polynucleotide treatment designed to support skin hydration, firmness and overall skin quality.
Each pre-filled 2ml syringe contains high-concentration polymerised polynucleotides at 25mg/ml, equivalent to a 2.5% formulation. The product is intended for professional aesthetic use and is commonly selected for mature, photoaged or lax skin where improvement in hydration, elasticity and tissue quality is desired. Part of the Nucleofill range manufactured in Italy by Promoitalia, it is designed to support biostimulation rather than create the volumising effect associated with conventional dermal fillers.
Nucleofill Strong Plus is the high-concentration option in the range:
Key specifications for Nucleofill Strong Plus:
Always refer to the current Nucleofill / Promoitalia product information and Instructions for Use before administration, and check the packaging, batch number and expiry date on the product supplied.
Nucleofill Strong Plus is an injectable polynucleotide treatment designed to support the appearance of regenerative processes within the skin. Polynucleotides are long-chain biological molecules used within regenerative aesthetic medicine to support tissue quality, hydration and fibroblast activity. Formulated at a relatively high concentration of 25mg/ml, Strong Plus is intended for treatment programmes where greater biostimulatory support is required, focusing on improving skin condition rather than adding facial volume.
Nucleofill Strong Plus contains polymerised polynucleotides at 25mg/ml, equivalent to a 2.5% concentration. The high-concentration formulation is designed to support skin hydration, firmness, elasticity, tissue quality, collagen-related processes and overall skin revitalisation, with the specific treatment plan based on patient assessment and the manufacturer’s recommended protocol. Positioned as a biostimulatory treatment, its purpose is to support processes within the skin associated with the appearance of repair and renewal — polynucleotides may help support fibroblast activity and the extracellular environment associated with structural skin components, which may help improve the visible appearance of reduced firmness, loss of elasticity, poor texture, age-related changes, photoaged skin and dehydration. Supplier information also describes antioxidant support among the intended benefits, since oxidative stress can contribute to visible skin ageing.
Nucleofill Strong Plus is designed to help replenish moisture and support hydration, which may help skin appear plumper, smoother, fresher, more supple, more radiant and less crepey, and may help soften the appearance of superficial lines caused by dehydration. As loss of collagen and elastin contributes to visible ageing and reduced firmness, it is used within programmes aimed at supporting the appearance of improved firmness, elasticity, skin tone, tissue quality and a more refreshed look. Results vary according to patient age, skin condition, lifestyle, treatment area and protocol.
Nucleofill Strong Plus should not be confused with a conventional volumising dermal filler. Its main purpose is skin biostimulation and improvement in the appearance of tissue quality — it is not intended primarily to create projection, reshape facial contours, provide substantial structural volume or replace a conventional volumising filler. It is generally selected where the objective is improvement in skin quality rather than facial augmentation.
Nucleofill Strong Plus may be used in suitable areas where improvement in skin quality, hydration and firmness is desired. Commonly listed treatment areas include:
The exact treatment area should be selected according to the manufacturer’s instructions, patient anatomy and professional assessment, with treatment individualised to clinical goals.
Nucleofill Strong Plus is intended for administration by appropriately trained healthcare and aesthetic professionals with suitable knowledge of relevant and vascular anatomy, injection techniques, patient assessment, aseptic technique, product handling, recognition of complications, emergency management and aftercare. Purchase or possession does not establish competence to administer injectable treatments.
Before administering, confirm patient identity, complete an appropriate consultation, review medical history, allergies and previous aesthetic treatments, assess the treatment area, confirm treatment goals, discuss expected outcomes and potential adverse effects, obtain appropriate consent, check the packaging and expiry date, ensure the syringe is intact and confirm appropriate emergency procedures are available. Treatment should only proceed where clinically appropriate. Maintain appropriate aseptic technique throughout — hand hygiene, correct skin preparation, sterile equipment, avoiding touching sterile components, maintaining syringe sterility, disposing of needles immediately and following local infection-control procedures.
Temporary reactions may occur, including redness, swelling, tenderness, bruising, small injection-site papules, mild itching and temporary sensitivity — most mild local reactions settle without intervention, and patients should be given clear aftercare advice and guidance on symptoms requiring review. As with all injectable aesthetic procedures, adverse events are possible, which may include persistent swelling, inflammation, infection, hypersensitivity, nodules, prolonged tenderness, vascular compromise and other injection-related complications. Any unexpected, persistent or worsening reaction should be assessed promptly by an appropriately qualified practitioner.
Injectable aesthetic treatments carry a risk of vascular complications. Potential warning signs may include unexpected or disproportionate pain, blanching, mottling, dusky skin colour, delayed capillary refill, coolness, progressive skin changes, visual disturbance or neurological symptoms. Suspected vascular compromise requires immediate assessment and appropriate evidence-based management, and visual or neurological symptoms following facial injection should be treated as a medical emergency.
Treatment should only be undertaken after appropriate patient assessment. Reasons to avoid or postpone may include active infection, inflamed skin, open wounds, known hypersensitivity to product components, relevant uncontrolled medical conditions, recent procedures affecting the treatment area, pregnancy or breastfeeding where treatment is not appropriate, and other contraindications in the Instructions for Use — always refer to the current IFU for complete information.
The syringe is for single-patient use: do not reuse the syringe or needles, share the product between patients, retain opened product for another patient or attempt to resterilise it; discard any unused product per the manufacturer’s instructions and local clinical waste procedures. Aftercare may include avoiding unnecessary touching of treated areas, excessive heat and strenuous exercise for an appropriate period, excessive UV exposure and additional procedures until the area has settled, using suitable skincare and sun protection, and contacting the practitioner if persistent or unusual symptoms occur. Store per the manufacturer’s packaging and IFU — in original packaging, within the specified temperature range, protected from excessive heat, freezing (where applicable) and direct sunlight, and secure from children and unauthorised access. Do not use after the expiry date or if the packaging or syringe appears damaged.
Nucleofill Strong Plus 1 × 2ml is intended for use by appropriately trained healthcare and aesthetic professionals. Practitioners remain responsible for patient selection, clinical assessment, treatment planning, appropriate injection technique, aseptic practice, recognition and management of complications, emergency preparedness, aftercare and follow-up.
Compare insurance quotes from trusted partners.
167 products
252 sold